Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Bacteria transplants could help canine gut disease, study finds
FMT could provide viable short-term treatment for chronic enteropathy.
Donor bacteria could provide relief for chronic bowel inflammation.

A new study has revealed the clinical benefits of bacterial transplants to dogs with gut disease.

Researchers from the Royal (Dick) School of Veterinary Studies found that just one treatment of a donor bacteria provided temporary relief for chronic bowel conditions in dogs.

Chronic enteropathy, an inflammatory condition of the gut, is often compared to Crohn’s disease in humans. It frequently causes persistent signs such as diarrhoea, vomiting and weight loss.

It is often treated through dietary changes, anti-inflammatory medicines and immune-suppressing drugs. However, in recent years, faecal microbiota transplantation (FMT) has become a potential alternative.

The study involved seven dogs that were experiencing chronic enteropathy. Each dog received a single FMT from two healthy donor dogs, followed by clinical assessments over the following 90-day period.

The dogs’ progress was recorded using a clinical activity scale, which measures the severity of the disease. It records data on symptoms such as appetite, weight loss, vomiting and diarrhoea.

Before their treatment, the dogs had an average score of eight. This means that their symptoms indicated a moderate to severe level of disease.

One week after treatment, the average score dropped to three. By day 30, the average score had fallen to one.

Researchers say that FMT could therefore provide a practical and viable short-term treatment for dogs with chronic enteropathy, although its exact mechanism remains unclear.

The study also investigate how glycerol, a substance used to preserve frozen samples, might impact the effectiveness of FMT.

Glycerol was not found to be necessary for maintaining FMT effectiveness. Frozen FMT examples could therefore remain viable without glycerol, providing they are used after a single thaw and are not refrozen.

Silke Salavati, personal chair of small animal gastroenterology, said: “Our findings suggest that while faecal microbiota transplantations can provide meaningful clinical improvement for dogs with chronic enteropathy, the way it works might not be through permanently changing the microbiota.

“This raises interesting questions about what exactly in the transplant is driving the benefits - whether it's the bacteria themselves or other bioactive compounds they produce.”

The full study can be found in the Journal of Veterinary Internal Medicine.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.